CELL EXPANSION DEVICES

Development of bioreactors for advanced cell culture and tissue engineering.

COMPANY

Cellex is an innovative start-up Company founded in June 2018

PRODUCT

Cell cultures suspended in a fluid environment are the basis for the production of medical products

FINANCIAL

Cellex’ revenues are mainly related to the sales of SUSPENCE

CELL EXPANSION DEVICES

CORE BUSINESS

Cellex’s core business is the development of bioreactors for advanced cell culture and tissue engineering.

Cellex is currently focused on the design, development and production of SUSPENCE®, a highly innovative scalable bioreactor that keeps cells in suspension in a culture chamber, allowing them to grow and reach maturity in dynamic conditions.

MAIN APPLICATIONS

INSULINE

VACCINES

RECOMBINANT PROTEINS

CHEMOTHERAPY

The Product

The devices currently used for this type of production are highly inefficient. Some, like blenders, hit the cells with their blades, breaking them during cultivation. Others do not provide sufficient oxygen and nutrients to ensure proliferation and development.

NUMBERS

%

IMPROVEMENT IN VACCINE PRODUCTION

%

IMPROVEMENT IN CELL PRODUCTION YIELD

%

IMPROVEMENT IN CELL CLUSTER PRODUCTION

%

TURNOVER INCREASE SINCE FOUNDATION

The Team

The team responsible for the activities of CELLEX is a highly skilled and deeply experienced technical and commercial team.

They are specialists in the field of medical technology, manufacturing, marketing, quality and regulatory management, project management and strategy, business management and communication.

Giuseppe Falvo
D’Urso Labate

Giacomo
Di Benedetto

Katarzyna
Kolacz

Pieter
Van der Poel

Start up

Financials

In 2018, Cellex obtained a € 56.003,60 funding from the European Community and Lazio Regional Government, through the Institution Lazio Innova, within the program POR/FESR 2014-2020 – Azione 1.4.1 “Sostegno alla creazione e al consolidamento di start-up innovative ad alta intensità di applicazione di conoscenza e alle iniziative di spinoff della ricerca in ambiti in linea con le Strategie di specializzazione intelligente [anche tramite la promozione delle fasi di pre-seed e seed e attraverso strumenti di venture capital]”- Asse prioritario 1 – Ricerca e Innovazione. – Bando Pre-SEED – Determinazione 27 marzo 2017, n. G03793. This grant allowed Cellex to test its technology in the case of higher fluid volumes, paving the way for tailoring SUSPENCE for the needs of Pharma industry.